Hetero strengthens position in India with launch of biosimilar Rituximab

Published On 2015-08-04 07:51 GMT   |   Update On 2015-08-04 07:51 GMT
Advertisement
Hetero has launched the drug under the brand name ‘Maball’ to be used for treatment of certain types of cancers and rheumatoid arthritis

Drug firm Hetero has recently launched its new drug Maball, a biosimilar Rituximab in India to be used for treatment of cancers and rheumatoid arthritis. With the launch of Maball, Hetero's aims to strengthen its position in the biosimilar market in India, and has enabled the company to join select biotech company’s bandwagon of complex monoclonal antibodies (MAB's).
Advertisement

The company also has plans to introduce affordable biosimilar Rituximab drugs outside India to highlight its commitment and strategy on investment in biosimilars.

The product "will be marketed and distributed by Hetero Healthcare Ltd, a group company of Hetero", the firm said in a statement.

The company's product is a biosimilar version of Roche's Rituximab, Hetero said.

It further said, "Rituximab is used alone or with other drugs to treat non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. It is also used for the treatment of other indications such as rheumatoid arthritis."

Hetero Drugs is an Indian Pharmceutical firm started in 1993, and is headquartered at hydrabad
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News